170 related articles for article (PubMed ID: 29225263)
1. A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma.
Ri M; Suzuki K; Iida S; Hatake K; Chou T; Taniwaki M; Watanabe N; Tsukamoto T
Intern Med; 2018 Apr; 57(7):939-946. PubMed ID: 29225263
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.
Hamaguchi T; Tsuji A; Yamaguchi K; Takeda K; Uetake H; Esaki T; Amagai K; Sakai D; Baba H; Kimura M; Matsumura Y; Tsukamoto T
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1021-1029. PubMed ID: 30284603
[TBL] [Abstract][Full Text] [Related]
4. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
Miyazaki O; Sekine K; Nakajima N; Ichimura E; Ebara K; Nagai D; Onda T; Miyakawa Y; Okamoto K; Morino T
Int J Cancer; 2014 Jan; 134(1):218-23. PubMed ID: 23775066
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
Hamaguchi T; Doi T; Eguchi-Nakajima T; Kato K; Yamada Y; Shimada Y; Fuse N; Ohtsu A; Matsumoto S; Takanashi M; Matsumura Y
Clin Cancer Res; 2010 Oct; 16(20):5058-66. PubMed ID: 20943763
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
Eur J Cancer; 2010 Feb; 46(3):650-8. PubMed ID: 20015633
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
8. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
Matsumura Y
Adv Drug Deliv Rev; 2011 Mar; 63(3):184-92. PubMed ID: 20561951
[TBL] [Abstract][Full Text] [Related]
10. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Zhang R; Saito R; Mano Y; Sumiyoshi A; Kanamori M; Sonoda Y; Kawashima R; Tominaga T
Drug Deliv; 2016 Oct; 23(8):2780-2786. PubMed ID: 26330269
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Saito Y; Matsumura Y
Int J Cancer; 2009 Jun; 124(11):2505-11. PubMed ID: 19189401
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
14. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
[TBL] [Abstract][Full Text] [Related]
15. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.
Coriat R; Faivre SJ; Mir O; Dreyer C; Ropert S; Bouattour M; Desjardins R; Goldwasser F; Raymond E
Int J Nanomedicine; 2016; 11():6207-6216. PubMed ID: 27920527
[TBL] [Abstract][Full Text] [Related]
18. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
20. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
